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Abstract. Decoy receptor 3 (DcR3) is a soluble secreted 
protein that belongs to the tumor necrosis factor receptor 
(TNFR) superfamily. DcR3 inhibits the Fas ligand (FasL)/Fas 
apoptotic pathway by binding to FasL, competitively with Fas 
receptor. Previous studies have reported that overexpression 
of DcR3 has been detected in various human malignancies 
and that DcR3 functions as a ‘decoy’ for FasL to inhibit FasL-
induced apoptosis. In addition, recent studies have revealed 
that DcR3 has ‘non-decoy’ functions to promote tumor cell 
migration and invasion, suggesting that DcR3 may play 
important roles in tumor progression by decoy and non-decoy 
functions. We have previously reported that overexpression of 
DcR3 was observed in human malignant fibrous histiocytoma 
(MFH), however, the roles of DcR3 in MFH have not been 
studied. In the present study, to elucidate the roles of DcR3 
in tumor progression of MFH, we examined the effects of 
DcR3 inhibition on cell apoptosis, migration and invasion in 
human MFH cells. siRNA knockdown of DcR3 enhanced the 
FasL-induced apoptotic activity and significantly decreased 
cell migration and invasion with a decrease in the activation 
of phosphatidylinositol 3 kinase (PI3K)/Akt and matrix metal-
loproteinase (MMP)-2. The findings in this study strongly 
suggest that DcR3 plays important roles in tumor progression 
of human MFH by decoy as well as non-decoy functions and 
that DcR3 may serve as a potent therapeutic target for human 
MFH.
Introduction
Malignant fibrous histiocytoma (MFH), which has recently 
been classified as undifferentiated pleomorphic sarcoma 
(UPS), is the most common high-grade soft tissue sarcoma 
that occurs in late adult life (1,2). Advances in the treatment 
of MFH have led to multidisciplinary treatment, including 
surgery, chemotherapy and radiation therapy, resulting in great 
improvements in the quality of life of patients with the disease, 
however, the chemotherapy and radiation therapy strategies 
for MFH are not as effective as those for other malignancies. 
After adequate local treatment and adjuvant therapy, ~50% of 
patients invariably relapse with local recurrence and distant 
metastasis, hence the prognosis of patients with MFH is 
poor (1,3,4). Therefore, it is necessary to elucidate the factors 
contributing to tumor progression and metastasis in MFH and 
to establish more effective therapeutic strategies against MFH.
Decoy receptor 3 (DcR3) is a newly identified member of 
the tumor necrosis factor receptor (TNFR) superfamily. DcR3 
lacks a transmembrane domain and is thought to be a soluble 
secreted protein. DcR3 is known to act as a decoy receptor for 
Fas ligand (FasL) (5), LIGHT (6) and TL1A (7). Among these, 
FasL, which is produced by activated T cells and natural killer 
cells, is the most important regulator of cellular apoptosis 
through the death receptor pathway. DcR3 competes with Fas 
receptor for binding to FasL and inhibits the FasL/Fas apoptotic 
pathway. Fas receptor has an intracellular death domain that 
triggers the extrinsic apoptotic signaling pathway by activating 
caspase-8, which can induce apoptosis through the activation 
of caspase-3, -6 and -7 and poly (ADP-ribose) polymerase 
(PARP). The FasL/Fas apoptotic pathway is a central regulator 
of apoptosis in mammals to eliminate malignant tumor cells 
and resistance to this apoptotic pathway is thought to be one of 
‘Decoy’ and ‘non-decoy’ functions of DcR3 promote malignant 
potential in human malignant fibrous histiocytoma cells
MITSUNORI TODA1,  TERUYA KAWAMOTO1,  TAKESHI UEHA2,  KENTA KISHIMOTO1,  HITOMI HARA1,   
NAOMASA FUKASE1,  YASUO ONISHI1,  RISA HARADA1,  MASAYA MINODA1,   
MASAHIRO KUROSAKA1  and  TOSHIHIRO AKISUE1
1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Chuo-ku, Kobe 650-0017;  
2NeoChemir Inc., Sannomiya Chuo-building 4F, Chuo-ku, Kobe 651-0087, Japan
Received April 24, 2013;  Accepted June 7, 2013
DOI: 10.3892/ijo.2013.1999
Correspondence to: Dr Teruya Kawamoto, Department of 
Orthopaedic Surgery, Kobe University Graduate School of Medicine, 
7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
E-mail: trykwmt@med.kobe-u.ac.jp
Abbreviations: MFH, malignant fibrous histiocytoma; UPS, 
undifferentiated pleomorphic sarcoma; DcR3, decoy receptor 3; 
TNFR, tumor necrosis factor receptor; FasL, Fas ligand; LIGHT, 
lymphotoxin-like, exhibits inducible expression and competes with 
herpes simplex virus (HSV) glycoprotein D (gD) for HVEM, a 
receptor expressed by T lymphocytes; TL1A, TNF-like molecule 1A; 
PARP, poly (ADP-ribose) polymerase; HUVEC, human umbilical 
vein endothelial cell; MMP, matrix metalloproteinase; ERK, 
extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; 
EBV, Epstein-Barr virus; HTLV-1, human T cell leukemia virus 
type 1; ECM, extracellular matrix; PI3K, phosphatidylinositol 3 
kinase
Key words: DcR3, apoptosis, migration, invasion, matrix 
metalloproteinase
TODA et al:  DcR3 PROMOTES MALIGNANT POTENTIAL IN HUMAN MFH704
the hallmarks of malignant tumors (8,9). Therefore, DcR3 has 
been thought to contribute to tumor progression by inhibiting 
FasL-induced apoptosis of tumor cells.
Recent studies have demonstrated that DcR3 also func-
tions as an effector molecule independently of the FasL/Fas 
apoptotic pathway. DcR3 overexpression promotes migration 
and invasion of nasopharyngeal carcinoma cells (10). In breast 
cancer cells, DcR3 suppression decreases both migration and 
invasion (11). Moreover, several studies have revealed that 
DcR3 promotes migration of HUVECs with an increased 
expression of matrix metalloproteinase (MMP)-2 (12) and 
that DcR3 can activate various signaling kinases such as Akt, 
extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun 
N-terminal kinase (JNK) and p38 mitogen-activated protein 
kinase (p38) (13-17). These reports strongly indicate that 
DcR3, in addition to its role as a decoy receptor for FasL, may 
function as a modulator of malignant progression in cancer 
cells.
Overexpression of DcR3 has been reported in various 
malignancies such as lung and colon cancers (5), EBV or 
HTLV-1 associated lymphomas (18), malignant gliomas (19) 
and pancreatic adenocarcinomas (20). Furthermore, we have 
previously reported that overexpression of DcR3 was observed 
in bone and soft tissue sarcomas (21). Several studies have also 
revealed that DcR3 overexpression is associated with distant 
metastasis and overall survival in human cancers (22-27). In 
the development of metastasis, MMPs are thought to play 
important roles in tumor cells by degrading the extracellular 
matrix (ECM) (28,29). The increased expression of certain 
MMPs correlates with tumor expansion, invasiveness and poor 
prognosis of patients with malignant tumors (30). Among the 
MMP subtypes, activation of MMP-2 has been observed in 
MFH (31,32), therefore, MMP-2 is thought to contribute to the 
metastatic potential of human MFH.
Based on previous studies, DcR3 may contribute to tumor 
progression by not only neutralizing FasL-induced apoptosis 
but also by promoting tumor migration and invasion, which are 
important for the development of metastasis. We hypothesized 
that DcR3 may play important roles in tumor progression and 
metastatic potential in human MFH through the inhibition of 
the apoptotic pathway and the signaling pathway that is related 
to migration and invasion. In the present study, we evaluated 
the effects of DcR3 inhibition on cell apoptosis, migration and 
invasion using human MFH cell lines to elucidate the roles of 
DcR3 in human MFH.
Materials and methods
Human MFH cell lines. Two human MFH cell lines, TNMY1 
and Nara-H, were used in this study. TNMY1 was previously 
established in our laboratory (33) and Nara-H was obtained 
from ScienStuff Co. (Nara, Japan) (34). Cells were grown in 
culture medium consisting of Dulbecco's modified Eagle's 
medium (DMEM; Sigma-Aldrich Co., St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich) and 100 U/ml penicillin/streptomycin solution 
(Sigma-Aldrich). Cell lines were routinely maintained at 37˚C 
in a humidified 5% CO2 atmosphere. For all experiments, we 
used the DMEM containing 10% FBS without the antibiotic 
solution.
Transfection of small interfering RNA (siRNA). To evaluate the 
effect of DcR3 knockdown, we transfected MFH cell lines with 
DcR3-specific small interfering RNA (siRNA). Briefly, 1 day 
before transfection, cells were seeded in 6-well culture plates 
in growth medium. Then, cells were transfected with 60 nmol 
of either a specific siRNA against human DcR3 (DcR3-si) 
(Invitrogen, Carlsbad, CA, USA) or a negative control siRNA 
(Ctrl-si) (Invitrogen) using Lipofectamine 2000 transfection 
reagent according to the manufacturer's protocol (Invitrogen).
Recombinant Fc, FasL and PI3K inhibitor treatment. After 
siRNA transfection, DcR3-si transfected cells were incubated 
in medium with 0 (DcR3-si cells) or 3 µg/ml of recombi-
nant DcR3-Fc (DcR3-si+DcR3-Fc cells; R&D Systems, 
Minneapolis, MN, USA), or 3 µg/ml of recombinant IgG-Fc 
(DcR3-si+IgG-Fc cells, as a control; R&D Systems) for 24 h. 
Ctrl-si transfected cells were incubated without any recombi-
nant Fc proteins (Ctrl-si cells).
To induce apoptosis, cells were treated with FasL (100 ng/
ml; Peprotech, Rocky Hill, NJ, USA) for 6 h after siRNA 
transfection and Fc treatment.
To evaluate kinase activities, cells were pretreated with 
0 or 20 µM of LY294002 [a phosphatidylinositol 3 kinase 
(PI3K) inhibitor; Cell Signaling Technology, Danvers, MA, 
USA] in DMSO (Wako, Osaka, Japan) for 2 h followed by a 
1-h treatment with DcR3-Fc or IgG-Fc.
Quantitative real-time PCR. We isolated total RNAs from cell 
lines using an RNeasy Mini kit according to the manufacturer's 
protocol (Qiagen, Valencia, CA, USA) and first strand cDNAs 
were transcribed. Quantitative real-time PCR (qRT-PCR) was 
performed in a 20-µl reaction mixture using the Power SYBR 
Green Master Mix reagent (Applied Biosystems, Foster City, 
CA, USA) on an ABI PRISM 7500 sequence detection system 
(Applied Biosystems). The PCR conditions were as follows: 
1 cycle at 95˚C for 10 min followed by 40 cycles at 95˚C for 
15 sec and 60˚C for 1 min. Primers for human DcR3, MMP-2 
and human β-actin (control) were synthesized by Hokkaido 
System Science (Hokkaido, Japan). Primer used were: DcR3: 
5'-TCAATGTGCCAGGCTCTTC-3' and 5'-AGCCACAAAG 
TCGATGACG-3'; MMP-2: 5'-ACAGCAGGTCTCAGCC 
TCAT-3' and 5'-TGCCTCTGGACAACACAGAC-3'; β-actin: 
5'-GATGAGATTGGCATGGCTTT-3' and 5'-CACCTTCA 
CCGTTCCAGTTT-3'. The values were normalized with those 
for β-actin and relative expression was analyzed using the 
∆∆Ct method.
Immunoblot analysis. Lysates were extracted from cells using 
a whole cell lysis buffer (Mammalian Protein Extraction 
Reagent, Thermo Scientific, Rockford, IL, USA) supplemented 
with a protease and phosphatase inhibitor mix (Roche Applied 
Science, Indianapolis, IN, USA). The protein content of 
lysates was then quantified using BCA Protein Assay reagent 
(Bio-Rad, Richmond, CA, USA). Samples containing equal 
amounts of protein were electrophoresed through 12% poly-
acrylamide gels and transferred onto PVDF membranes. After 
blocking membranes were incubated overnight at 4˚C with the 
following antibodies in CanGet Signal Solution 1 (Toyobo Co., 
Ltd., Osaka, Japan): anti-human DcR3 (1:1,000), anti-human 
Fas (1:1,000), anti-human PARP (1:1,000), anti-human cleaved 
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PARP (1:1,000), anti-human caspase-3 (1:1,000), anti-human 
cleaved caspase-3 (1:500), anti-human MMP-2 (1:1,000), anti-
human Akt (1:2,000), anti-human phosho-Akt (p-Akt; 1:1,000), 
anti-human ERK1/2 (1:2,000), anti-human phospho-ERK1/2 
(p-ERK1/2; 1:1,500), anti-human JNK (1:1,000), anti-human 
phospho-JNK (p-JNK; 1:1,000), anti-human p38 (1:1,000), 
anti-human phospho-p38 (p-p38; 1:1,000). All antibodies were 
purchased from Cell Signaling Technology. Following washes, 
membranes were incubated with the appropriate secondary 
antibody conjugated to horseradish peroxidase and were 
exposed with ECL Plus western blot detection system reagent 
(GE Healthcare Biosciences, Piscataway, NJ, USA). Antibody 
binding was detected by Chemilumino analyzer LAS-3000 
mini (Fujifilm, Tokyo, Japan). Membranes were reprobed with 
anti-human α-tubulin antibody (Sigma-Aldrich) to confirm 
equal protein loading.
Cell proliferation assays. To evaluate the involvement of 
DcR3 in MFH cell proliferation, we performed WST-8 
cell proliferation assay using Cell Counting Kit-8 (CCK-8; 
Dojindo Inc., Kumamoto, Japan). Cells were seeded in 
96-well culture plates at a density of 5x103 cells/well in 100 µl 
culture medium. After siRNA transfection and Fc treatment, 
cells were treated with or without FasL to induce apoptosis. 
At the indicated incubation times (0, 24 and 48 h), 10 µl of the 
CCK-8 solution was added into each well and incubated for 
1 h. Optical density was measured at a wavelength of 450 nm 
using a Model 680 Microplate Reader (Bio-Rad, Hercules, 
CA, USA). The relative number of viable cells in each well 
was calculated.
Cell migration assays. To evaluate the effect of DcR3 on MFH 
cell migration, we performed in vitro scratch wound healing 
assays as previously described (35). Cells in 6-well culture 
plates were transfected with siRNA and treated with recom-
binant Fc and then incubated to form a confluent monolayer. 
A denuded area was created by scraping with a sterile 200-µl 
pipette tip and each well was washed three times with PBS 
to remove floating cells. Scratch wounds were inspected with 
an inverted microscope (Zeiss, Oberkochen, Germany) and 
captured by Motic Images Plus 2.2S (Shimadzu, Kyoto, Japan) 
after 0, 12 and 24 h of wounding. The distance between the 
opposing edges of the wound was measured at three points and 
averaged on each image.
Cell invasion assays. The effect of DcR3 on cell invasion 
was assessed by Transwell chamber invasion assays, as 
previously described (36). After siRNA transfection and Fc 
treatment, 5x104 cells were placed in the upper wells of 24-well 
Transwell chambers (BioCoat Matrigel Invasion Chamber, 
Figure 1. siRNA knockdown of DcR3 and DcR3-Fc treatment in MFH cell lines. TNMY1 and Nara-H cells were transfected with either a specific siRNA 
against DcR3 (DcR3-si) or a negative control siRNA (Ctrl-si). Then, DcR3-si transfected cells were treated with PBS (DcR3-si), recombinant DcR3-Fc (DcR3-
si+DcR3-Fc), or recombinant IgG-Fc (DcR3-si+IgG-Fc) for 24 h. (A) DcR3 mRNA expression was analyzed by qRT-PCR (*P<0.05). (B) Protein expressions 
of DcR3, DcR3-Fc and Fas were evaluated by immunoblot analysis.
  A
  B
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BD Biosciences, Bedford, MA, USA) and the lower wells were 
filled with complete growth medium. The chambers were 
incubated for 30 h to allow cells to invade from the upper wells 
towards the lower wells. After incubation, non-invading cells 
on the upper surface of membranes were removed by scrub-
bing and invading cells on the lower surface of the membranes 
were fixed, inspected with a microscope and imaged. The 
number of invading cells was counted in three random fields.
Gelatin zymography. To evaluate the enzyme activity of 
MMP-2, we performed gelatin zymography as previously 
described (37). The cell culture supernatant in each well was 
collected and concentrated through an Amicon Ultra-4 10,000 
MWCO Centrifugal Filter Device (Millipore, Billerica, MA, 
USA) and samples were electrophoresed through 10% gelatin 
gels (Invitrogen). After electrophoresis, the gels were washed 
with renaturing buffer (Invitrogen) for 30 min, followed by 
incubation with developing buffer (Invitrogen) overnight at 
37˚C. The gels were stained with Coomassie Brilliant Blue 
R-250 Staining Solution (Bio-Rad) and clear bands of MMP-2 
were visible against the dark blue background.
Statistical analysis. Each experiment was performed inde-
pendently at least three times and data are presented as the 
mean ± standard deviation (SD). The statistical significance of 
the differences among means was evaluated by ANOVA with 
post hoc test. Results were considered significant at P<0.05.
Results
DcR3 knockdown enhanced FasL-induced apoptosis in 
human MFH cells. We performed transfection of DcR3-
siRNA and DcR3-Fc treatment to evaluate the effects of DcR3 
in MFH cells. In both MFH cell lines, DcR3-siRNA transfec-
tion strongly suppressed DcR3 mRNA (*P<0.05, Fig. 1A) and 
protein expression levels (Fig. 1B). DcR3-Fc treatment slightly, 
but not significantly, increased DcR3 expression, while IgG-Fc 
treatment did not affect DcR3 expression (Fig. 1B). Fas 
expression was not affected by DcR3-siRNA transfection or 
DcR3-Fc treatment (Fig. 1B).
Immunoblot analysis revealed that DcR3 knockdown or 
DcR3-Fc treatment without FasL treatment did not affect 
the expressions of caspase-3, PARP and their cleaved forms 
in either cell line (Fig. 2A). FasL treatment strongly induced 
the cleavage of caspase-3 and PARP in DcR3-si and DcR3-
si+IgG-Fc cells, while the cleaved forms of capase-3 and 
PARP were barely detected in Ctrl-si cells (Fig. 2B). The 
increased expressions of cleaved capase-3 and cleaved PARP 
were suppressed by DcR3-Fc treatment in both MFH cell lines 
(DcR3-si+DcR3-Fc cells; Fig. 2B).
A previous report demonstrated that DcR3 knockdown 
with FasL treatment significantly suppressed cell proliferation 
in human pancreatic adenocarcinoma cells (38), therefore, we 
evaluated the effect of DcR3 inhibition with FasL treatment on 
MFH cell proliferation. siRNA transfection and recombinant 
Fc treatment without FasL treatment did not affect cell prolif-
eration in either cell line (Fig. 2C), whereas, cell proliferation 
was significantly decreased in DcR3-si and DcR3-si+IgG-Fc 
cells with FasL treatment (*P<0.05, Fig. 2D). Moreover, 
DcR3-Fc treatment increased cell proliferation in DcR3-si 
cells to the same levels as in Ctrl-si cells (DcR3-si+DcR3-Fc 
cells; Fig. 2D).
DcR3 knockdown significantly suppressed MFH cell migra-
tion and invasion. We evaluated the effects of DcR3 on MFH 
cell migration and invasion to investigate the non-decoy func-
tions of DcR3 in human MFH. In the in vitro scratch wound 
healing assays, DcR3 knockdown significantly decreased 
cell migration in both MFH cell lines at 12 and 24 h after 
wounding and DcR3-Fc treatment significantly restored the 
migration ability compared with control cells, respectively 
(*P<0.05, Fig. 3). Significant changes in cell migration were 
not observed in either MFH cell line with IgG-Fc treatment 
(Fig. 3).
Next, we performed the transwell chamber invasion assays 
to evaluate the role of DcR3 in MFH cell invasion. In both 
cell lines, the number of invading cells in DcR3-siRNA trans-
fected cells was decreased to 61% (TNMY1, Fig. 4A) and 64% 
(Nara-H, Fig. 4B) of that in control cells (*P<0.05). In addi-
tion, DcR3-Fc treatment after DcR3 knockdown significantly 
restored the invasiveness in both cell lines (*P<0.05, Fig. 4).
DcR3 activated the PI3K/Akt pathway in MFH cells. Because 
DcR3 has been reported to be involved in the activation of 
various kinases (13-17), we evaluated the effect of DcR3 
expression on the activation of signaling kinases in MFH cells. 
DcR3 knockdown and/or DcR3-Fc treatment did not affect the 
expressions of ERK1/2, JNK, p38 and their phosphorylated 
forms (Fig. 5A) and interestingly, DcR3 knockdown signifi-
cantly decreased Akt phosphorylation in both MFH cell lines, 
which was restored by DcR3-Fc treatment (Fig. 5B). The 
expression of phosphorylated Akt was suppressed by DcR3-
siRNA and/or pretreatment with the PI3K inhibitor, LY294002 
(LY) (Fig. 5B).
DcR3 regulated MMP-2 expression via the PI3K/Akt pathway 
in human MFH cells. As previous reports suggest that DcR3 
may affect MMP-2 regulation via the PI3K/Akt pathway 
(12,17,39), we evaluated the effect of DcR3 inhibition on 
MMP-2 expression through the PI3K/Akt pathway in MFH 
cells. qRT-PCR analysis revealed that MMP-2 mRNA expres-
sion was significantly suppressed by DcR3 knockdown and 
was restored by DcR3-Fc treatment in both MFH cell lines 
(*P<0.05, Fig. 6A). Immunoblot analysis and gelatin zymog-
raphy showed that the protein expression and enzyme activity 
of MMP-2 were strongly reduced by siRNA knockdown of 
DcR3 (Fig. 6B). Consistent with the Akt phosphorylation 
(Fig. 5B), both the expression and enzyme activity of MMP-2 
were increased by DcR3-Fc treatment and were significantly 
suppressed by LY294002 pretreatment (Fig. 6B).
Discussion
DcR3 has been identified as a decoy receptor for FasL in lung 
and colon cancers (5) and recent studies have suggested that 
DcR3 acts as a modulator of cellular functions such as migra-
tion and invasion (10,11). It has been demonstrated that DcR3 
overexpression is associated with tumor metastasis and prog-
nosis of patients with various malignancies (5,18-26). These 
findings strongly indicate that DcR3 may be an attractive 
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Figure 2. Effects of DcR3 knockdown with or without FasL treatment on apoptotic activity and cell proliferation in human MFH cells. After siRNA transfec-
tion and recombinant Fc treatment, cells were incubated for 6 h with or without FasL (100 ng/ml) to induce apoptosis. (A and B) Immunoblot analysis of 
caspase-3, PARP and their cleaved forms. (C and D) Cell proliferation assays after 24 and 48 h of incubation (*P<0.05).
  A
  B
  C
  D
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candidate as a novel therapeutic target for cancer treatment. 
We have previously reported the overexpression of DcR3 in 
musculoskeletal malignancies including MFH (21), however, 
the functional roles of DcR3 in MFH have not been studied. 
Therefore, we investigated the roles of DcR3 as a decoy 
receptor for FasL and as an effector molecule in migration and 
invasion in human MFH cells.
Because resistance to apoptosis is a characteristic property 
of malignant tumor cells to escape from immune attack by 
host immune systems (8), we first focused on the function of 
DcR3 as a decoy receptor for FasL. Many cancers, in spite 
of their Fas expression, can be resistant to FasL-induced 
apoptosis and several mechanisms may be responsible for the 
decreased sensitivity to FasL-induced apoptosis, including 
DcR3 (40). Yang et al reported that siRNA knockdown of 
DcR3 increased FasL-induced apoptosis in human pancre-
atic adenocarcinoma cells, which highly express DcR3 (38). 
In this study, we demonstrated that siRNA knockdown of 
DcR3 enhanced FasL-induced apoptotic activity in human 
MFH cell lines and that FasL treatment with DcR3 inhibition 
significantly suppressed MFH cell proliferation. In addition, 
DcR3-Fc treatment after DcR3 knockdown suppressed the 
increased FasL-induced apoptotic activity and induced MFH 
cell proliferation. The expression of Fas receptor in MFH cells 
was not affected by DcR3 knockdown or DcR3-Fc treatment. 
These results strongly suggest that DcR3 may contribute to 
MFH cell growth by inhibiting FasL-induced apoptosis as a 
decoy receptor.
Moreover, several studies have demonstrated that DcR3 
functions as an effector molecule in various cells, indepen-
dently of the FasL/Fas pathway, by regulating migration 
and invasion abilities (10,11), ERK stimulation in gastric 
cancers (41), increasing adhesion in monocytes via PI3K/Akt 
activation (17) and regulating proliferation and migration of 
Figure 3. Effect of DcR3 on MFH cell migration. In vitro scratch wound healing assays of siRNA transfected MFH cell lines [TNMY1 (A) and Nara-H (B)] 
treated with recombinant Fc was used to evaluate cell migration. Dotted lines indicate the margins of migrating cells. The average wound distance of cell 
migration into the wound surface was determined under an inverted microscope 0, 12 and 24 h after wounding (*P<0.05).
  A
  B
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HUVECs via MMP-2 regulation (12). These reports suggested 
that DcR3 has non-decoy functions, which are independent of 
the FasL/Fas apoptotic pathway. In the present study, we found 
that DcR3 inhibition significantly decreased cell migration 
and invasion in human MFH cells and that DcR3-Fc treatment 
significantly increased both abilities. These results indicate 
that DcR3 may regulate cell migration and invasion in human 
MFH.
Previous studies have also suggested the involvement of 
DcR3 in kinase phosphorylation (13-17). Therefore, we further 
investigated the effect of DcR3 expression on the activation of 
signaling kinases involved in migration and invasion in MFH 
cells. We revealed that Akt phosphorylation, which is inhib-
ited by PI3K inhibition, was decreased by DcR3 knockdown 
and increased by DcR3-Fc treatment. Akt is a major signal 
transducer of the PI3K pathway, playing a pivotal role in the 
maintenance of cellular processes including cell growth, prolif-
eration, survival and metabolism (42-44). An increase in Akt 
activity has been detected in various cancers (42-44). In addi-
tion, Akt signaling enhances MMP-2 activity and promotes 
cell migration and invasion (42). Therefore, we investigated the 
effect of DcR3 on MMP-2 activity in the PI3K/Akt pathway. 
Consistent with the Akt phosphorylation, DcR3 knockdown 
decreased MMP-2 expression and activity and DcR3-Fc treat-
ment increased both the expression and activity of MMP-2, 
which were inhibited by PI3K inhibition. MMPs are thought 
to play a critical role in helping cancer cells invade through 
ECM degradation and form metastatic lesions (45). MMP-2, 
which is regulated by various kinases, is the most abundant 
among all MMPs (39,46) and has been reported to be upregu-
lated in MFH (31,32). Activation of both PI3K/Akt pathway 
and MMP-2 are known to increase cell migration and inva-
sion, leading to metastasis in various cancers (42,45). These 
findings indicate that DcR3 may regulate MMP-2 expression 
Figure 4. Effect of DcR3 on MFH cell invasion was assessed by transwell chamber invasion assays [TNMY1 (A) and Nara-H (B)]. After siRNA transfection 
and recombinant Fc treatment, cells were placed in the upper wells of 24-well transwell chambers. The chambers were incubated for 30 h and invading cells 
on the lower surface of the membranes were inspected with a microscope and counted in three random fields (*P<0.05).
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Figure 5. Effect of DcR3 on the activation of signaling kinases in MFH cells. (A) Immunoblot analyses were performed to detect the expression of ERK1/2, 
JNK, p38 and their phosphorylated forms in both MFH cell lines after siRNA transfection and recombinant Fc treatment. (B) Immunoblot analysis of Akt and 
phosphorylated Akt in both MFH cell lines treated with a PI3K inhibitor, LY294002 (LY) after siRNA transfection and recombinant Fc treatment.
Figure 6. Effects of DcR3 on the expression and activation of MMP-2 in MFH cells. TNMY1 and Nara-H cells were transfected with either control or DcR3 
siRNA and treated with recombinant Fc (DcR3 or IgG). DcR3-si+DcR3-Fc cells were also treated with the PI3K inhibitor, LY294002 (LY). (A) MMP-2 
mRNA expression was analyzed by qRT-PCR (*P<0.05). (B) Immunoblot analysis and gelatin zymography for MMP-2.
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via activation of the PI3K/Akt pathway and that this regula-
tion may be one of the important roles of DcR3 as an effector 
molecule facilitating the progression or metastasis of MFH.
In conclusion, we demonstrated that in human MFH cells 
DcR3 may increase tumor progression as a decoy, promoting 
cell proliferation via inhibition of FasL-induced apoptosis 
and as a non-decoy, regulating cell migration and invasion by 
MMP-2 activation via the PI3K/Akt pathway (Fig. 7). Although 
further studies are needed to elucidate the roles of DcR3 in 
MFH tumor progression, our findings strongly indicate that 
DcR3 may be a potential therapeutic target in human MFH.
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